Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
5.86
+0.34 (6.16%)
At close: Jun 26, 2026, 4:00 PM EDT
5.82
-0.04 (-0.77%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Precigen Employees
Precigen had 160 employees as of December 31, 2025. The number of employees increased by 17 or 11.89% compared to the previous year.
Employees
160
Change (1Y)
17
Growth (1Y)
11.89%
Revenue / Employee
$197,469
Profits / Employee
-$2,396,363
Market Cap
2.09B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Viridian Therapeutics | 252 |
| Kardigan | 241 |
| Stoke Therapeutics | 170 |
| Taysha Gene Therapies | 99 |
PGEN News
- 9 days ago - Precigen Transcript: AGM 2026 - Transcripts
- 12 days ago - Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging - Accesswire
- 16 days ago - Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices - PRNewsWire
- 19 days ago - Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 27 days ago - Precigen presents long-term follow-up data from study of Papzimeos - TheFly
- 4 weeks ago - Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years - PRNewsWire
- 4 weeks ago - Precigen price target raised to $14 from $11 at H.C. Wainwright - TheFly
- 4 weeks ago - Precigen receives orphan drug exclusivity for papzimeos in the U.S. - TheFly